Fig. 4.

Modulation of HCC progression via cisplatin-coated liposomes co-loaded with miR-375. a Schematic representation of the nanocomplex NPC/miR-375 b TEM and c AFM characterization of the nanocomplex d Uptake of cisplatin in HepG2 cells measured by ICP-MS; miR-375 level in HepG2 cells measured by e FACS and f RT-qPCR. g Schematic illustration of the in vivo experimental model h Excised tumors and i volume from control and treated mice.

Reprinted (adapted) with permission from Yang et al. [50]